循環器ジャーナル71巻1号

2023年01月発行

特集 ここが変わった！循環器診療 最新スタンダード Ⅱ．循環器診療に関わる領域

腫瘍循環器学の新しい診療ガイドラインと今後の課題

著者： 佐瀬一洋¹ 木田圭亮²³⁴ 志賀太郎⁵

所属機関： ¹順天堂大学大学院医学研究科臨床薬理学 ²聖マリアンナ医科大学薬理学 ³聖マリアンナ医科大学病院循環器内科 ⁴聖マリアンナ医科大学病院リハビリテーション科 ⁵がん研究会有明病院腫瘍循環器・循環器内科

ページ範囲：P.122 - P.127

ここが変わった！
●過去のスタンダード
　・がん治療関連心機能障害（CTRCD）として抗がん剤や放射線の心毒性に対応していた．
　・心エコーは添付文書記載時のみ，アントラサイクリン前でなくトラスツズマブ前に実施していた．
　・がん薬物治療中の無症候性心機能低下は，心毒性として治療を中止していた．
●現在のスタンダード
　・がん治療関連心血管毒性（CTR-CVT）として新薬や多彩な循環器疾患にも対応する．
　・ベースライン・リスク評価に基づき，CTR-CVTの予防と早期診断の管理を個別化する．
　・CTR-CVTを発症した場合でも，可能な限り循環器支援によるがん治療完遂を目指す．

参考文献

1）小室一成（監修），日本腫瘍循環器学会編集委員会（編集）．腫瘍循環器診療ハンドブック．メジカルビュー社，2020

2）佐瀬一洋（編集）．〔特集〕プレシジョン・メディシン時代における腫瘍循環器学の重要性．循環器ジャーナル2021 ; 69 : 501-658．

3）Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association（EHA）, the European Society for Therapeutic Radiology and Oncology（ESTRO）and the International Cardio-Oncology Society（IC-OS）. Eur Heart J 2022［E-pub ahead of print］.

4）Snipelisky D, Park JY, Lerman A, et al. How to Develop a Cardio-Oncology Clinic. Heart Fail Clin 2017 ; 13 : 347-59.

5）Shelburne N, Simonds NI, Adhikari B, et al. Changing Hearts and Minds : Improving Outcomes in Cancer Treatment-Related Cardiotoxicity. Curr Oncol Rep 2019 ; 21 : 9.

6）Levis BE, Binkley PF, Shapiro CL. Cardiotoxic effects of anthracycline-based therapy : what is the evidence, and what are the potential harms? Lancet Oncol 2017 ; 18 : e445-e56.

7）Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer : a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015 ; 16 : e123-e36.

8）Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology（ESC）. Eur Heart J 2016 ; 37 : 2768-801.

9）Armenian SH, Lucchetti C, Barac A, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2017 ; 35 : 893-911.

10）Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment : ESMO consensus recommendations. Ann Oncol 2020 ; 31 : 171-90.

11）Dang CT, Yu AF, Jones LW, et al. Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer : Getting to the Heart of the Matter. J Clin Oncol 2016 ; 34 : 1030-3.

12）Leong DP, Lenihan DJ. Clinical Practice Guidelines in Cardio-Oncology. Heart Fail Clin 2022 ; 18 : 489-501.

13）Alexandre J, Cautela J, Ederhy S, et al. Cardiovascular Toxicity Related to Cancer Treatment : A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc 2020 ; 9 : e018403.

14）Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies : an International Cardio-Oncology Society（IC-OS）consensus statement. Eur Heart J 2022 ; 43 : 280-99.

15）Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies : a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020 ; 22 : 1945-60.

16）Celutkiene J, Pudil R, Lopez-Fernandez T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies : a position statement on behalf of the Heart Failure Association（HFA）, the European Association of Cardiovascular Imaging（EACVI）and the Cardio-Oncology Council of the European Society of Cardiology（ESC）. Eur J Heart Fail 2020 ; 22 : 1504-24.

17）Pudil R, Mueller C, Celutkiene J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies : a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail 2020 ; 22 : 1966-83.

18）Padegimas A, Clasen S, Ky B. Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends Cardiovasc Med 2020 ; 30 : 22-28.

19）佐瀬一洋．アントラサイクリン系抗がん剤の心毒性に対するデクスラゾキサンの心保護作用．循環器内科2022 ; 91 : 797-804．

20）Mitchell JD, Cehic DA, Morgia M, et al. Cardiovascular Manifestations From Therapeutic Radiation : A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society. JACC CardioOncol 2021 ; 3 : 360-80.

21）Leong DP, Cosman T, Alhussein MM, et al. Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity. JACC CardioOncol 2019 ; 1 : 1-10.

22）Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer : ASCO Clinical Practice Guideline Update. J Clin Oncol 2020 ; 38 : 496-520.

23）佐瀬一洋．がん関連血栓塞栓症（CAT）に対する抗凝固療法の現状と今後の課題．循環器内科2020 ; 88 : 678-86．

24）Sase K, Mukai M, Fujiwara Y. Clinical Practice Guidelines in Cardio-Oncology-A Sea of Opportunity. JACC CardioOncol 2022 ; doi : 10.1016/j.jaccao.2022.11.001.

25）Billingham L, Malottki K, Steven N. Research methods to change clinical practice for patients with rare cancers. Lancet Oncol 2016 ; 17 : e70-e80.

26）Lancellotti P, Suter TM, Lopez-Fernandez T, et al. Cardio-Oncology Services : rationale, organization, and implementation. Eur Heart J 2019 ; 40 : 1756-63.